A detailed history of Concord Wealth Partners transactions in Repligen Corp stock. As of the latest transaction made, Concord Wealth Partners holds 10 shares of RGEN stock, worth $1,247. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Previous 10 -0.0%
Holding current value
$1,247
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 27, 2023

BUY
$162.42 - $220.56 $1,624 - $2,205
10 New
10 $1,000
Q4 2020

Feb 16, 2021

BUY
$148.08 - $206.57 $1,480 - $2,065
10 New
10 $2,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Concord Wealth Partners Portfolio

Follow Concord Wealth Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

News

Stay updated on Concord Wealth Partners with notifications on news.